Silexion Therapeutics Ltd. (SLXNW) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Jul 28Jul 31Aug 5Aug 12Aug 17Aug 20Aug 28Sep 2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.1x

Market Cap

$15857.21

MomentumView details →

1D Return

+23.89%

YTD Return

−46.15%

RSI (14)

44.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.1x

Market Cap

$15857.21

RSI (14)

44.7

MomentumView details →

1D Return

+23.89%

YTD Return

−46.15%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

−328.73%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+12.05%

FCF YoY

−17.70%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+97.73%

EBITDA YoY

+12.21%

EarningsView details →

EPS (Actual)

−$5.17

EPS Surprise

75.61%

Beats (12Q)

3/12

Next Q EPS Est

−$9.10

Avg Surprise (4Q)

24.76%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

32.05x

Current Ratio

0.94x

Quick Ratio

0.94x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−13.96M

Op. CF (TTM)

−12.43M

Next earningsNov 18, 2026 →

Latest newsMore news →

Silexion Therapeutics Corp received a notice from Nasdaq on August 18, 2026, stating it no longer complies with the minimum shareholders' equity requirement under Rule 5550(b)(1), and the company plans to appeal before the Nasdaq Hearings Panel.15d ago

Silexion Therapeutics Corp. announced the pricing of a public offering of 3,846,161 ordinary shares and series E warrants at a combined price of $0.65 per share, expected to close on August 13, 2026.24d ago

Similar companies

Syros Pharmaceuticals, Inc.SYRS Psyence Biomedical Ltd. WarrantPBMWW Surrozen, Inc.SRZNW Cardio Diagnostics Holdings, Inc.CDIOW Carisma Therapeutics, Inc.CARM Moolec Science S.A.MLECW Find similar companies →

Latest newsMore news →

Silexion Therapeutics Corp received a notice from Nasdaq on August 18, 2026, stating it no longer complies with the minimum shareholders' equity requirement under Rule 5550(b)(1), and the company plans to appeal before the Nasdaq Hearings Panel.15d ago Silexion Therapeutics Corp. announced the pricing of a public offering of 3,846,161 ordinary shares and series E warrants at a combined price of $0.65 per share, expected to close on August 13, 2026.24d ago